



(11) **EP 2 576 791 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C12N 15/75 ^(2006.01) **A61K 35/74** ^(2015.01)

(86) International application number:
PCT/US2011/037602

(48) Corrigendum issued on:
21.12.2016 Bulletin 2016/51

(87) International publication number:
WO 2011/149852 (01.12.2011 Gazette 2011/48)

(45) Date of publication and mention
of the grant of the patent:
19.10.2016 Bulletin 2016/42

(21) Application number: **11787200.2**

(22) Date of filing: **23.05.2011**

(54) **METHODS AND COMPOSITIONS USING LISTERIA FOR ADJUVANT TREATMENT OF CANCER**

VERFAHREN UND ZUSAMMENSETZUNGEN MIT LISTERIA ZUR HILFSBEHANDLUNG VON
KREBS

PROCÉDÉS ET COMPOSITIONS UTILISANT LA LISTERIA POUR UN TRAITEMENT DU CANCER
PAR ADJUVANT

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(74) Representative: **Brasnett, Adrian Hugh et al**
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE (GB)

(30) Priority: **23.05.2010 US 347447 P**

(43) Date of publication of application:
10.04.2013 Bulletin 2013/15

(56) References cited:
WO-A1-2010/040135 WO-A2-2008/094188
US-A- 6 051 237 US-A1- 2007 207 171

(73) Proprietor: **Aduro BioTech, Inc.**
Berkeley, CA 94710 (US)

(72) Inventors:
• **DUBENSKY, Thomas, W.**
Piedmont, CA 94611 (US)
• **BROCKSTEDT, Dirk, G.**
Richmond, CA 94804 (US)
• **LEONG, Meredith**
Oakland, CA 94611 (US)
• **BAHJAT, Keith, S.**
Portland, OR 97239 (US)

- **S. H. KIM ET AL: "High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action", CANCER RESEARCH, vol. 69, no. 14, 15 July 2009 (2009-07-15), pages 5860-5866, XP055080598, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-08-4855**
- **HASSAN ET AL: "Mesothelin targeted cancer immunotherapy", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 44, no. 1, 22 October 2007 (2007-10-22), pages 46-53, XP022392314, ISSN: 0959-8049, DOI: 10.1016/J.EJCA.2007.08.028**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 576 791 B8

- D. T. LE ET AL: "A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction", CLINICAL CANCER RESEARCH, vol. 18, no. 3, 1 February 2012 (2012-02-01), pages 858-868, XP055080595, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-11-2121